Toshiaki Takakura
Overview
Explore the profile of Toshiaki Takakura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
13
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takakura T, Akamatsu H, Washioka A, Murakami E, Shibaki R, Shimizu T, et al.
Respirol Case Rep
. 2024 Sep;
12(9):e01401.
PMID: 39220096
Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge. We report the...
2.
Iguchi H, Akamatsu H, Hirai Y, Nakaya T, Fusamoto A, Yata Y, et al.
Respirol Case Rep
. 2024 Aug;
12(8):e70007.
PMID: 39161537
Neoadjuvant therapy with nivolumab improves event-free survival (EFS) in patients with resectable non-small cell lung cancer, and a pathological complete response is a predictor of longer EFS. We assessed metabolic...
3.
Takakura T, Shimizu T, Yamamoto N
Jpn J Clin Oncol
. 2024 May;
54(8):837-846.
PMID: 38704241
Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds...
4.
Nakaya T, Hirai Y, Akamatsu H, Kojima F, Iguchi H, Fusamoto A, et al.
Respirol Case Rep
. 2024 Apr;
12(5):e01358.
PMID: 38680669
The standard treatment for resectable non-small cell lung cancer (NSCLC) located in the superior sulcus is neoadjuvant chemoradiotherapy followed by highly invasive resection. Based on the results of the CheckMate...
5.
Murakami E, Akamatsu H, Teraoka S, Takakura T, Takase E, Tanaka M, et al.
Cancer Med
. 2024 Mar;
13(4):e6839.
PMID: 38457231
Background: Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)-based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires...
6.
Takakura T, Yamamoto N
Gan To Kagaku Ryoho
. 2023 Jul;
50(7):768-772.
PMID: 37496218
HER2 alterations are divided into 3 categories: gene mutation, gene amplification, and protein overexpression. Unlike breast and gastric cancers, where gene amplification and protein overexpression are therapeutic targets, genetic mutations...
7.
Takakura T, Kanemura H, Sakai K, Nishio K, Nakagawa K, Hayashi H
JTO Clin Res Rep
. 2023 Jun;
4(6):100523.
PMID: 37287496
Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of...
8.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, et al.
Cancer Sci
. 2020 Oct;
112(1):72-80.
PMID: 33084148
CD24, a heavily glycosylated glycosylphosphatidylinositol-anchored surface protein, inhibits phagocytosis as potently as CD47. The relationship between such anti-phagocytic factors and the immune response with immune-checkpoint inhibitors (ICI) remains unexplored. We...